Viking Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company, is advancing a dual GLP-1/GIP agonist, VK2735, for treating obesity for both subcutaneous and oral administration
Spend time with loved ones
TESAMORELIN has been shown to significantly reduce visceral fat in patients with HIV-associated lipodystrophy, leading to improved body composition and metabolic health
This powerful antioxidant exists in two different forms, including the oxidized and reduced states
The GLP-1RA group also had a 32% higher risk of excess weight gain (gaining more than recommended), a 30% higher risk of diabetes during pregnancy, a 29% higher risk of hypertensive disorders during pregnancy, and a 34% higher risk of preterm delivery